James Kasuboski

James Kasuboski, Ph.D., is a Partner and Head of Research at Luma Group, a venture focused on improving human health and longevity.6 He has an extensive background in biomedical research and the biotech and pharmaceutical sectors, with over 15 years of experience in biomedical research and more than a decade of expertise in the biotech and pharmaceutical industries.17

Professional Experience

Dr. Kasuboski has been involved in investments across more than 18 companies, ranging from pre-clinical to clinical development stages.1 His career in venture capital includes:

• Partner and Head of Research at Luma Group (current position)1
• Vice President at OMX Ventures2
• Venture investor at RA Capital2
• Director at Boehringer Ingelheim Venture Fund23

During his time in venture capital, he has served on the boards of several companies, including:

• Enara Bio
• Avilar Therapeutics
• Endor Therapeutics
• Tilos Therapeutics (acquired by Merck & Co.)
• Rewind Therapeutics23

Education

Dr. Kasuboski's educational background includes:

• Ph.D. in Molecular and Cellular Biology from the University of Notre Dame13
• B.S. in Biology with a minor in Chemistry from Hillsdale College in Michigan13

Investment Philosophy

As a venture capitalist, Dr. Kasuboski focuses on early-stage biotech investing and company creation.3 He looks for three key factors when evaluating potential investments, which he calls the "three T's":

1. Team
2. Technology
3. Tenacity4

His approach involves being a "utility player" in the venture capital world, providing mentorship, getting involved in day-to-day tasks, and helping companies grow and succeed.4

Dr. Kasuboski's research interests include the effects of therapeutic small molecule inhibitors on cancer and cell division.5 Through his work at Luma Group, he continues to seek opportunities to improve human health and longevity.6